Metsera, Inc. (NASDAQ:MTSR - Get Free Report) gapped up prior to trading on Tuesday after Guggenheim raised their price target on the stock from $56.00 to $62.00. The stock had previously closed at $30.39, but opened at $32.35. Guggenheim currently has a buy rating on the stock. Metsera shares last traded at $37.42, with a volume of 959,269 shares.
MTSR has been the subject of several other reports. Evercore ISI started coverage on Metsera in a research note on Tuesday, February 25th. They issued an "outperform" rating for the company. Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They issued an "overweight" rating on the stock. Finally, Bank of America initiated coverage on Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price objective for the company.
View Our Latest Report on MTSR
Hedge Funds Weigh In On Metsera
Several large investors have recently bought and sold shares of MTSR. Strs Ohio acquired a new stake in Metsera during the 1st quarter worth $76,000. New York State Common Retirement Fund bought a new position in shares of Metsera in the 1st quarter worth $131,000. Corebridge Financial Inc. acquired a new stake in shares of Metsera during the first quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Metsera during the first quarter worth $248,000. Finally, MetLife Investment Management LLC bought a new stake in Metsera in the first quarter valued at about $254,000.
Metsera Price Performance
The business's 50 day moving average price is $23.40.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Articles
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
